Grufity logo
Grufity logo

Latest Soleus Capital Management, L.P. Stock Portfolio

$2.90Billion | No. of Holdings #97

Soleus Capital Management, L.P. Performance

2026 Q2+15.01%
YTD+12.38%
2025+25.13%

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

On 2026-08-11, the fund reported it's updated stock portfolio. In the 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $2.9 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Soleus Capital Management, L.P. are KRYS, CELC, TGTX. The fund has invested 12% of it's portfolio in KRYSTAL BIOTECH INC and 6.1% of portfolio in CELCUITY INC. <br><br> The fund managers got completely rid off VAXCYTE INC (PCVX), ICON PLC (ICLR) and TRAVERE THERAPEUTICS INC (TVTX) stocks. They significantly reduced their stock positions in NATERA INC (NTRA), NEOGENOMICS INC (NEO) and CORCEPT THERAPEUTICS INC (CORT). Soleus Capital Management, L.P. opened new stock positions in ERASCA INC (ERAS), PARABILIS MEDICINES INC and LEGEND BIOTECH CORP (LEGN). The fund showed a lot of confidence in some stocks as they added substantially to RIGEL PHARMACEUTICALS INC (RIGL), INSMED INC (INSM) and PROCEPT BIOROBOTICS CORP (PRCT).
Soleus Capital Management, L.P. Equity Portfolio Value
Last Reported on: 11 Aug, 2026
$2.90Billion
  as of Aug 11, 2026

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of 15.01% in the last quarter. In trailing 12 months, it's portfolio return was 64.53%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
erasca inc49,464,000
parabilis medicines inc40,099,000
legend biotech corp34,800,400
unitedhealth group inc33,250,400
palisade bio inc27,303,100
supernus pharmaceuticals24,185,200
nuvectis pharma inc18,390,000
capricor therapeutics inc18,342,600
New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker% Inc.
rigel pharmaceuticals inc18,335
insmed inc780
procept biorobotics corp526
argenx se470
avalo therapeutics inc274
inspire med sys inc235
mbx biosciences inc188
arcus biosciences inc158
Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker% Reduced
natera inc-99.16
neogenomics inc-94.29
corcept therapeutics inc-93.12
veracyte inc-92.19
axogen inc-91.6
twist bioscience corp-91.47
cullinan therapeutics inc-87.81
iovance biotherapeutics inc-85.00
Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
travere therapeutics inc -16,221,700
immunic inc -4,995,000
vaxcyte inc -22,399,800
cytomx therapeutics inc. -1,410,000
jasper therapeutics inc -242,105
icon plc -21,246,700
eton pharmaceuticals inc -4,106,280
dexcom inc -8,792,000
Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 86.1% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare86.1
Others13.6

Market Cap. Distribution

Soleus Capital Management, L.P. has about 25.8% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • SMALL-CAP
  • LARGE-CAP
  • UNALLOCATED
  • MICRO-CAP
  • MEGA-CAP
Category%
MID-CAP29.8
SMALL-CAP28.5
LARGE-CAP24.4
UNALLOCATED13.6
MICRO-CAP2.2
MEGA-CAP1.4

Stocks belong to which Index?

About 61% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200054.1
Others39
S&P 5006.9
Top 5 Winners (%)%
URGN
urogen pharma ltd
92.2 %
KPTI
karyopharm therapeutics inc
75.4 %
CCCC
c4 therapeutics inc
73.2 %
TWST
twist bioscience corp
63.2 %
PGNY
progyny inc
61.9 %
Top 5 Winners ($)$
KRYS
krystal biotech inc
118.6 M
TGTX
tg therapeutics inc
75.6 M
NVCR
novocure ltd
43.4 M
TWST
twist bioscience corp
36.8 M
ALKS
alkermes plc
25.6 M
Top 5 Losers (%)%
CNTX
context therapeutics inc
-78.7 %
NSPR
inspiremd inc
-57.0 %
ADGI
invivyd inc
-32.9 %
QNRX
quoin pharmaceuticals ltd
-26.7 %
INSM
insmed inc
-22.9 %
Top 5 Losers ($)$
PODD
insulet corp
-46.4 M
CNTX
context therapeutics inc
-14.5 M
CELC
celcuity inc
-14.2 M
UTHR
united therapeutics corp del
-10.6 M
GERN
geron corp
-8.9 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 97 stocks in it's portfolio. About 48.9% of the portfolio is in top 10 stocks. PODD proved to be the most loss making stock for the portfolio. KRYS was the most profitable stock for Soleus Capital Management, L.P. last quarter.

$2.90BTotal Value
115Positions
11 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Soleus Capital Management, L.P., last reported on 11 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ARGX
Argenx Se

Argenx Se

ARGX
Soleus Capital Management, L.P.'s holding in Argenx Se over time
0.64%19,955
$18.51M
0.64%
increased 470.14 percentadded
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Soleus Capital Management, L.P.'s holding in Belite Bio Inc over time
0.27%50,524
$7.78M
0.27%
new position